India to Canada Pharmaceutical Export

The India-Canada pharmaceutical trade corridor has experienced significant growth over the past decade, evolving from modest exchanges to a robust and dynamic partnership. In the fiscal year 2024–25, India's pharmaceutical exports to Canada reached approximately $540 million, marking a substantial increase from previous years. This growth trajectory underscores the expanding demand for Indian pharmaceutical products in the Canadian market.

Key milestones in this bilateral trade relationship include the successful completion of a historic trade mission to India in November 2017, which facilitated new partnerships between Indian and Canadian businesses. (canada.ca) Additionally, the launch of the Comprehensive Economic Partnership Agreement (CEPA) negotiations in March 2026 signifies a strategic effort to further enhance economic ties, with a target to increase bilateral trade to $50 billion by 2030.

India holds a significant position in Canada's pharmaceutical import landscape. In the fiscal year 2024–25, India's pharmaceutical exports to Canada were valued at approximately $540 million, contributing to a total bilateral trade of $8.6 billion. This positions India as a key supplier, reflecting the strategic importance of this trade corridor for Canada.

Between 2024 and 2026, several developments have influenced the India-Canada pharmaceutical trade corridor. Notably, in March 2026, the two nations agreed to strengthen their economic partnership by finalizing the CEPA negotiations, aiming to increase bilateral trade to $50 billion by 2030. This agreement is expected to further enhance the trade of pharmaceutical products, among other sectors, by reducing trade barriers and improving market access.

As of January 1, 2026, Canada maintains a Most-Favored-Nation (MFN) tariff rate of zero for pharmaceutical products classified under HS codes 3003 and 3004, which encompass finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. This zero-duty rate applies to imports from all World Trade Organization (WTO) member countries, including India. Therefore, Indian pharmaceutical exports to Canada benefit from this preferential tariff treatment.

In addition to the MFN rate, Canada has established preferential duty rates for certain trade partners through various trade agreements. However, as of March 2026, there are no specific preferential duty rates for Indian pharmaceutical products under any existing trade agreements. Consequently, Indian pharmaceutical exports to Canada are subject to the standard MFN tariff rates.

Currently, there is no Free Trade Agreement (FTA) between India and Canada. However, in November 2025, the Prime Ministers of both countries announced their intention to launch negotiations toward a Comprehensive Economic Partnership Agreement (CEPA). This agreement aims to enhance bilateral trade and investment, potentially impacting sectors such as pharmaceuticals. Public consultations were conducted from December 13, 2025, to January 27, 2026, to gather input from stakeholders on the proposed CEPA. As of March 2026, discussions are ongoing, and no formal agreement has been finalized. (international.canada.ca)

Canada's intellectual property (IP) framework, particularly concerning patents, significantly influences the entry of generic drugs into the market. The country adheres to international IP standards, including those set by the World Trade Organization's Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. This adherence provides patent holders with exclusive rights, typically lasting 20 years from the filing date. Generic manufacturers, including those from India, must navigate this exclusivity period, which can delay the introduction of generic versions of patented drugs. Additionally, Canada's regulatory environment includes provisions for compulsory licensing under specific circumstances, allowing the government to authorize the production of a patented product without the consent of the patent holder, primarily to address public health needs. However, such measures are rarely invoked and are subject to stringent conditions. Therefore, Indian generic pharmaceutical companies must carefully assess the patent landscape and regulatory environment to strategize their market entry into Canada effectively.